A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors (Q38819541)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 April 2017

Language	Label	Description	Also known as
English	A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors	scientific article published on 26 April 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

drug interaction

0 references

5

object named as

Ylva Terelius

0 references

author name string

Anna-Karin Sohlenius-Sternbeck

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Gabrielle Meyerson

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Ann-Louise Hagbjörk

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sanja Juric

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Ylva Terelius

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

26 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1-9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Telaprevir: pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Diazepam interaction with antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Exploring concepts of in vitro time-dependent CYP inhibition assays

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Accumulation of caffeine in healthy volunteers treated with furafylline

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Validated assays for human cytochrome P450 activities

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Effect of Mibefradil on CYP3A4 In Vivo

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Predicting in vivo drug interactions from in vitro drug discovery data

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs

1 reference

https://api.crossref.org/works/10.1080%2F00498254.2017.1323136

21 January 2018

Identifiers

10.1080/00498254.2017.1323136

1 reference

https://api.fatcat.wiki/v0/release/a2gxmxymxzexljvdskxvy6y5vi

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_a2gxmxymxzexljvdskxvy6y5vi

1 reference

https://api.fatcat.wiki/v0/release/a2gxmxymxzexljvdskxvy6y5vi

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/a2gxmxymxzexljvdskxvy6y5vi

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38819541&oldid=2126205055"